Global mTORC-1 Inhibitors Pipeline Insights Review 2015

. Procardia (Nifedipine) with no Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/r87kfx/mtorc1) has announced the addition of the "mTORC-1 Inhibitors -Pipeline Insights" report to their offering. mTORC-1 Inhibitors Pipeline Insights provides the in-depth analysis of the pipeline assets across the mTORC-1 Inhibitors. Buy Basil online About Stalevo (Carbidopa Levodopa Entacapone) The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. http://webmd-consult.blogspot.com Dexone (Dexamethasone) The mTORC-1 Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage. mTORC-1 Inhibitors Pipeline Insights Report covers the mTORC-1 Inhibitors pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. Buy Zithromax (Azithromycin) with no prescription The Report also provides mTORC-1 Inhibitors related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. Endace The Report also highlights the discontinued and inactive projects in pipeline for mTORC-1 Inhibitors. Scope - The report provides a mTORC-1 Inhibitors Landscape across the globe - The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information - Coverage of the mTORC-1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for mTORC-1 Inhibitors and also provide company profiling - Pipeline products coverage based on various stages of development from NDA filings to discovery. - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/r87kfx/mtorc1

Global Pseudomonas Infections Pipeline Insights Review 2015

. Reminyl (Galantamine) without Rx DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/9c46dx/pseudomonas) has announced the addition of the "Pseudomonas Infections-Pipeline Insights" report to their offering. This Pseudomonas Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. Buy Arthritis - Muscle Pain Relief online Buy Robaxin (Methocarbamol) without prescription A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Pseudomonas Infections. http://medicalquestionanswers.wordpress.com About Effexor Xr (Venlafaxine) with no Rx This report provides information on the therapeutic development based on the Pseudomonas Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. Augmentin (Amoxicillin / Clavulanate ) with free Rx The report also covers the companies information involved in the therapeutic development of the products. Buy Elixophyllin without prescription It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Pseudomonas Infections - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Pseudomonas Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Pseudomonas Infections and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type For more information visit .researchandmarkets.com/research/9c46dx/pseudomonas

Pivotal Phase II Study Showed Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Lung Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that in the large pivotal Phase II study, BIRCH, the investigational cancer immunotherapy atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumors (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1). Buy Ocuflox (Ofloxacin) The study showed the amount of PD-L1 expressed by a person’s cancer correlated with their response to the medicine. Buy Indocin Sr (Indomethacin) with no Rx Adverse events were consistent with what has been previously observed for atezolizumab. “We are encouraged by the number of people who responded to atezolizumab and maintained their response during the study, which is particularly meaningful for people who had received several prior treatments,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. About Female Cialis (Tadalafil) without Rx “We plan to present results at an upcoming medical meeting and will discuss these data as well as results from our other lung cancer studies with health authorities to bring this medicine to patients as quickly as possible.’’ Earlier this year, the FDA granted atezolizumab a Breakthrough Therapy Designation for the treatment of people whose NSCLC expresses PD-L1 and who progressed during or after standard treatments (e.g., platinum-based chemotherapy and appropriate targeted therapy for EGFR mutation-positive or ALK-positive disease). About Doxepin with no prescription This designation is designed to expedite the development and review of medicines intended to treat serious diseases. Super Kamagra (Sildenafil with Dapoxetine) with free Rx We have seven Phase III studies evaluating atezolizumab alone or in combination with other medicines as a potential new treatment for people with early and advanced stages of lung cancer. About the BIRCH Study BIRCH is an open-label, multicenter, single-arm Phase II study that evaluated the safety and efficacy of atezolizumab in 667 people with locally advanced or metastatic NSCLC whose disease expressed PD-L1. Buy Weightlifting Gloves online PD-L1 expression was assessed on both tumor cells (TC) and tumor-infiltrating immune cells (IC) with an investigational immunohistochemistry test (IHC) being developed by Roche Diagnostics. http://web-md.blogspot.com Eligibility criteria included people whose tumors were determined to express PD-L1 with an IHC score of TC2/3 or IC2/3. People in the study received a 1200-milligram intravenous dose of atezolizumab every three weeks. The primary endpoint of the study was ORR. Secondary endpoints included duration of response (DoR), overall survival (OS), progression-free survival (PFS) and safety. Results from BIRCH will be presented at an upcoming medical meeting. About Lung Cancer According to the American Cancer Society, it is estimated that more than 221,000 Americans will be diagnosed with lung cancer in 2015, and NSCLC accounts for 85 percent of all lung cancers. It is estimated that approximately 60 percent of lung cancer diagnoses in the United States are made when the disease is in the advanced stages. About atezolizumab Atezolizumab (also known as MPDL3280A; anti-PDL1) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1. Atezolizumab is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on the surface of T cells. By inhibiting PD-L1, atezolizumab may enable the activation of T cells. All studies of atezolizumab include the evaluation of an investigational IHC test that uses the antibody SP142 to measure PD-L1 expression on both tumor cells and infiltrating immune cells. The goal of PD-L1 as a biomarker is to identify those people most likely to benefit when treated with atezolizumab alone, and to determine which people may benefit most from a combination of atezolizumab and another medicine. There are 11 ongoing or planned Phase III studies of atezolizumab across certain kinds of lung, kidney, breast and bladder cancer. About Genentech in Cancer Immunotherapy For more than 30 years, Genentech has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever to bring personalized cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each person with a treatment tailored to harness his or her own immune system to fight cancer. Genentech is studying more than 20 investigational medicines, seven of which are in clinical trials. In every study we are evaluating biomarkers to identify which people may be appropriate candidates for our medicines. For more information visit .gene.com/immunotherapy. About Genentech Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit .gene.com.